Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion, Inc.
Coronavirus Update: Moderna’s Variant-Targeting Vaccine Moves Into Trial, J&J Looks Set For US Authorization
A round up of COVID-19 developments, also including news on the EMA beginning a rolling review of Celltrion's antibody therapy, and progress for Novavax and Moderna in Japan.
A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
Health Canada has approved Celltrion’s subcutaneous version of Remsima for rheumatoid arthritis, as Celltrion plans to expand indications for the infliximab biosimilar to allow it to also treat inflammatory bowel disease. The company has also established an offshoot in Canada that will allow it to sell Remsima SC directly.
- Generic Drugs
- OTC, Consumer
- Large Molecule
- Other Names / Subsidiaries
- Bio CDMO
- Celltrion Healthcare Hungary Kft